Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture

Leukemia

Volumn 27, Issue 9, 2013, Pages 1820-1825

  Conte, N ^a,b   Varela, I ^c   Grove, C ^a   Manes, N ^a   Yusa, K ^a   Moreno, T ^c   Segonds Pichon, A ^d   Bench, A ^e   Gudgin, E ^e   Herman, B ^f   Bolli, N ^a,e   Ellis, P ^a   Haddad, D ^a   Costeas, P ^g   Rad, R ^a   Scott, M ^e   Huntly, B ^e   Bradley, A ^a   Vassiliou, G S ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^c UNIVERSITY OF CANTABRIA   (Spain)

^d BABRAHAM INSTITUTE   (United Kingdom)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f AGILENT TECHNOLOGIES   (United Kingdom)

^g Centre for the Study of Haematological Malignacies   (Cyprus)

Author keywords

acute myeloid leukaemia; classification; diagnosis; MIDAS; minimal residual disease; next generation sequencing; targeted capture

Indexed keywords

CBL PROTEIN; CYTOCHROME P450 2D6; DNA; DNA METHYLTRANSFERASE 3A; EPIDERMAL GROWTH FACTOR RECEPTOR; FLT3 LIGAND; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; K RAS PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN;

ADULT; AGED; ALGORITHM; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL RESEARCH; COPY NUMBER VARIATION; DNA FRAGMENTATION; DNA LIBRARY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN GENOME; KARYOTYPE; LEUKEMIA; MALE; MUTATIONAL ANALYSIS; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROCESSING; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

ADULT; AGED; AGED, 80 AND OVER; EXONS; FEMALE; GENE DUPLICATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TANDEM REPEAT SEQUENCES;

EID: 84883743375     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.117     Document Type: Article

References (24)

1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458: 719-724.
2. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
3. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
4. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.
5. Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood 2011; 118: 6153-6163.
6. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278.
7. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776-2784.
8. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266. (Pubitemid 40110814)
9. Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002; 100: 2717-2723.
10. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
11. Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, Brockman W et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 2009; 27: 182-189.
12. Bullinger L, Armstrong SA. HELP for AML: methylation profiling opens new avenues. Cancer Cell 2010; 17: 1-3.
13. Hummel M, Bonnin S, Lowy E, Roma G. TEQC: an R package for quality control in target capture experiments. Bioinformatics 2011; 27: 1316-1317.
14. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010; 26: 841-842.
15. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079.
16. Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 2012; 28: 311-317.
17. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-576.
18. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-3080. (Pubitemid 29200800)
19. Love MI, Mysickova A, Sun R, Kalscheuer V, Vingron M, Haas SA. Modeling read counts for CNV detection in exome sequencing data. Stat Appl Genet Mol Biol 2011; 10.
20. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103: 3669-3676. (Pubitemid 38596280)
21. Sanz M, Burnett A, Lo-Coco F, Lowenberg B. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr Opin Oncol 2009; 21: 594-600.
22. Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross NC et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in480% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 2011; 25: 877-879.
23. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433.
24. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.